Monday - November 16, 2026
CUHK-led international study confirms rituximab reduces disease relapses in young children with nephrotic syndrome, paving the way for second-line treatment options
October 08, 2026
SHATIN, Hong Kong, Oct. 8 -- The Chinese University of Hong Kong posted the following news release:

* * *

CUHK-led international study confirms rituximab reduces disease relapses in young children with nephrotic syndrome, paving the way for second-line treatment options

*

Nephrotic syndrome (NS) is the most common glomerular disease in childhood, with over two-thirds of affected children suffering from repeated relapses, requiring high dose ste . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Click here for more information about our products